EP1519747A4 - Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma) - Google Patents
Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma)Info
- Publication number
- EP1519747A4 EP1519747A4 EP03721280A EP03721280A EP1519747A4 EP 1519747 A4 EP1519747 A4 EP 1519747A4 EP 03721280 A EP03721280 A EP 03721280A EP 03721280 A EP03721280 A EP 03721280A EP 1519747 A4 EP1519747 A4 EP 1519747A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- psma
- monoclonal antibodies
- human monoclonal
- prostate specific
- specific membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5998902A | 2002-01-28 | 2002-01-28 | |
US59989 | 2002-01-28 | ||
PCT/US2003/002448 WO2003064606A2 (en) | 2002-01-28 | 2003-01-28 | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1519747A2 EP1519747A2 (de) | 2005-04-06 |
EP1519747A4 true EP1519747A4 (de) | 2006-03-29 |
Family
ID=27658271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03721280A Withdrawn EP1519747A4 (de) | 2002-01-28 | 2003-01-28 | Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma) |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1519747A4 (de) |
JP (1) | JP2005518789A (de) |
KR (1) | KR20040077889A (de) |
CN (1) | CN1652821A (de) |
AU (1) | AU2003224604B2 (de) |
BR (1) | BR0307216A (de) |
CA (1) | CA2474616A1 (de) |
MX (1) | MXPA04007262A (de) |
NZ (1) | NZ534687A (de) |
WO (1) | WO2003064606A2 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
ES2559002T3 (es) | 2001-10-23 | 2016-02-10 | Psma Development Company, L.L.C. | Anticuerpos contra PSMA |
US20050191293A1 (en) * | 2003-12-10 | 2005-09-01 | Shrikant Deshpande | IP-10 antibodies and their uses |
EP1766093B1 (de) * | 2004-02-06 | 2011-06-15 | University of Massachusetts | Antikörper gegen clostridium difficile-toxine und ihre verwendung |
JP4734319B2 (ja) * | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
EP1791868B1 (de) | 2004-07-01 | 2011-02-23 | Novo Nordisk A/S | An die rezeptoren kir2dl1, -2, -3, jedoch nicht kir2ds4, bindende antikörper und deren therapeutische verwendung |
EP1836225B1 (de) | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
US7875278B2 (en) | 2005-02-18 | 2011-01-25 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
CN101124249B (zh) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | 抗前列腺特异性膜抗原(psma)的人单克隆抗体 |
CA2970873C (en) * | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
EP1726650A1 (de) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoklonale Antikörper und Einzelkettenantikörper Fragments gegen das zelloberflächen Prostataspezifische Membranantigen |
ES2397973T3 (es) * | 2006-03-14 | 2013-03-12 | Cancer Targeted Technology Llc | Inhibidores peptidomiméticos del PSMA, compuestos que los comprenden y métodos de utilización |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
DK2326350T3 (da) | 2008-09-08 | 2013-12-16 | Psma Dev Company L L C | Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller |
NZ591134A (en) * | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa) |
CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
EP2419451A4 (de) * | 2009-04-14 | 2012-11-14 | Proscan Rx Pharma Inc | Antikörper gegen prostataspezifisches membranantigen |
CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
CA2833019A1 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
RS53818B1 (en) | 2012-10-12 | 2015-06-30 | Spirogen Sàrl | PIROLOBENZODIAZEPINI I NJIHOVI conjugated |
CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
CN103333249A (zh) * | 2013-06-14 | 2013-10-02 | 广州康合生物科技有限公司 | 一种抗前列腺特异性膜抗原(psma)的单克隆抗体及其应用 |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10100126B2 (en) * | 2015-03-10 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind PSMA |
ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
KR101704379B1 (ko) * | 2015-10-27 | 2017-02-08 | (주)알테오젠 | 항체-약물 접합체 및 그 제조방법 |
WO2017164678A2 (ko) * | 2016-03-23 | 2017-09-28 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 |
WO2017201488A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
BR112019010602A2 (pt) * | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
EP3589662A4 (de) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Induzierbares monovalentes antigenbindendes protein |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
BR112020007196A2 (pt) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | proteínas triespecíficas e métodos de uso |
CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
JP2022514262A (ja) | 2018-12-17 | 2022-02-10 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
WO2021164692A1 (zh) * | 2020-02-18 | 2021-08-26 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
US20230201366A1 (en) | 2021-11-19 | 2023-06-29 | Adc Therapeutics Sa | Anti-psma conjugates |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994029457A2 (en) * | 1993-06-09 | 1994-12-22 | Unilever N.V. | Process for producing fusion proteins comprising scfv fragments by a transformed mould |
WO2001009192A1 (en) * | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
WO2001053353A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Recombinant antibodies to human interkleukin-1 beta |
WO2002002641A1 (en) * | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
WO2003034903A2 (en) * | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
WO2004020588A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
WO2004050850A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
US20040175385A1 (en) * | 1998-08-31 | 2004-09-09 | The Regents Of The University Of Carlifornia | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
-
2003
- 2003-01-28 KR KR10-2004-7011643A patent/KR20040077889A/ko not_active Application Discontinuation
- 2003-01-28 JP JP2003564202A patent/JP2005518789A/ja active Pending
- 2003-01-28 AU AU2003224604A patent/AU2003224604B2/en not_active Ceased
- 2003-01-28 WO PCT/US2003/002448 patent/WO2003064606A2/en active IP Right Grant
- 2003-01-28 EP EP03721280A patent/EP1519747A4/de not_active Withdrawn
- 2003-01-28 BR BR0307216-9A patent/BR0307216A/pt not_active IP Right Cessation
- 2003-01-28 CN CNA038073714A patent/CN1652821A/zh active Pending
- 2003-01-28 NZ NZ534687A patent/NZ534687A/en unknown
- 2003-01-28 MX MXPA04007262A patent/MXPA04007262A/es unknown
- 2003-01-28 CA CA002474616A patent/CA2474616A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994029457A2 (en) * | 1993-06-09 | 1994-12-22 | Unilever N.V. | Process for producing fusion proteins comprising scfv fragments by a transformed mould |
US20040175385A1 (en) * | 1998-08-31 | 2004-09-09 | The Regents Of The University Of Carlifornia | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
WO2001009192A1 (en) * | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
WO2001053353A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Recombinant antibodies to human interkleukin-1 beta |
WO2002002641A1 (en) * | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
WO2003034903A2 (en) * | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
WO2004020588A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
WO2004050850A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
Non-Patent Citations (3)
Title |
---|
DONOVAN G P ET AL: "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), pages 818, XP001204629, ISSN: 0197-016X * |
HOLMES E H: "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 3, 2001, pages 511 - 519, XP002988381, ISSN: 1354-3784 * |
LIU H ET AL: "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 17, 1 September 1997 (1997-09-01), pages 3629 - 3634, XP001080132, ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
CA2474616A1 (en) | 2003-08-07 |
JP2005518789A (ja) | 2005-06-30 |
KR20040077889A (ko) | 2004-09-07 |
CN1652821A (zh) | 2005-08-10 |
EP1519747A2 (de) | 2005-04-06 |
WO2003064606A3 (en) | 2005-02-03 |
NZ534687A (en) | 2007-10-26 |
BR0307216A (pt) | 2005-12-20 |
MXPA04007262A (es) | 2004-10-29 |
AU2003224604B2 (en) | 2007-06-14 |
WO2003064606A2 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1519747A4 (de) | Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma) | |
PL1851250T3 (pl) | Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA) | |
HK1153649A1 (zh) | 治療性抗 單克隆抗體 | |
IL161705A0 (en) | Human monoclonal antibodies to dendritic cells | |
EP1633785A4 (de) | Humane monoklonale antikörper gegen protektives antigen von bacillus anthracis | |
CY2012019I1 (el) | Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20 | |
IL157274A0 (en) | Human monoclonal antibodies to fc alpha receptor (cd89) | |
IL173273A0 (en) | Modified human igf-1r antibodies | |
HK1077226A1 (en) | Human monoclonal antibodies against cd25 | |
IL179672A (en) | Monoclonal antibodies against 3 cd human | |
IL172242A0 (en) | Antibodies specific for cancer associated antigen sm5-1 and uses thereof | |
AU2003209059A1 (en) | Human monoclonal antibodies against membrane proteins | |
IL180789A0 (en) | Human monoclonal antibodies against human il-4 | |
IL172511A0 (en) | Specific human antibodies | |
EP1618897A4 (de) | Lipidmembran-struktur mit anti-mt-mmp-monoklonalem antikörper | |
FI20020807A0 (fi) | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita | |
EP1559725A4 (de) | Antikörper mit antigenerkennung | |
SI1851250T1 (sl) | Humano monoklonsko protitelo proti za prostato specifičnemu membranskemu antigenu (PSMA) | |
EP1446416A4 (de) | Tumorspezifische monoklonale antikörper | |
ZA200200730B (en) | Human monoclonal antibodies to prostate specific membrane antigen. | |
GB0325391D0 (en) | Human monoclonal antibodies | |
GB0016824D0 (en) | Human monoclonal antibodies | |
GB0017139D0 (en) | Human monoclonal antibodies | |
SI1656391T1 (sl) | Modificirana humana IGF-1R protitelesa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040820 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060213 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1079085 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060517 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1079085 Country of ref document: HK |